cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc2ldq1s
title: CCDC 2395495: Experimental Crystal Structure Determination

description: Related Article: Aichen Shi, Guimin Zhao, Ronghao Yang, Xiaoyun Liu, Fangfang Huang, Zhicai Chen, Wei Jiang, Yanpei Wang, Xin Ai, Zhihua Ma, Yuanyuan Li, Shiyang Shao|2025|Chem.Eng.Journal|507|160102|doi:10.1016/j.cej.2025.160102
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2ldq2t
title: CCDC 2395496: Experimental Crystal Structure Determination

description: Related Article: Aichen Shi, Guimin Zhao, Ronghao Yang, Xiaoyun Liu, Fangfang Huang, Zhicai Chen, Wei Jiang, Yanpei Wang, Xin Ai, Zhihua Ma, Yuanyuan Li, Shiyang Shao|2025|Chem.Eng.Journal|507|160102|doi:10.1016/j.cej.2025.160102
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2jvh63
title: CCDC 2349155: Experimental Crystal Structure Determination

description: Related Article: N. Vlahakis, A. Clauss, J.A. Rodriguez|2025|IUCrJ|12|223|doi:10.1107/S2052252524012132
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2jvh74
title: CCDC 2349156: Experimental Crystal Structure Determination

description: Related Article: N. Vlahakis, A. Clauss, J.A. Rodriguez|2025|IUCrJ|12|223|doi:10.1107/S2052252524012132
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2jvh85
title: CCDC 2349157: Experimental Crystal Structure Determination

description: Related Article: N. Vlahakis, A. Clauss, J.A. Rodriguez|2025|IUCrJ|12|223|doi:10.1107/S2052252524012132
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2jvh96
title: CCDC 2349158: Experimental Crystal Structure Determination

description: Related Article: N. Vlahakis, A. Clauss, J.A. Rodriguez|2025|IUCrJ|12|223|doi:10.1107/S2052252524012132
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2jvhb7
title: CCDC 2349159: Experimental Crystal Structure Determination

description: Related Article: N. Vlahakis, A. Clauss, J.A. Rodriguez|2025|IUCrJ|12|223|doi:10.1107/S2052252524012132
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.14979458
title: Socioeconomic Data of Spanish Provinces – A University Project

description: This project explores the relationship between economic indicators and crime rates, aiming to develop predictive models based on data analysis. Conducted as part of our university coursework in data management, we analyze various economic factors to assess their influence on crime trends. Our research includes data processing, statistical modeling, and insights that contribute to understanding crime prediction.
DOI: 10.5281/zenodo.14979459
title: Socioeconomic Data of Spanish Provinces – A University Project

description: This project explores the relationship between economic indicators and crime rates, aiming to develop predictive models based on data analysis. Conducted as part of our university coursework in data management, we analyze various economic factors to assess their influence on crime trends. Our research includes data processing, statistical modeling, and insights that contribute to understanding crime prediction.
DOI: 10.15468/dl.arjzw7
title: Occurrence Download

description: A dataset containing 121 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mesoplodon stejnegeri True, 1885",
 "HasCoordinate is true",
 "DecimalLatitude is greater than -90",
 "DecimalLongitude is greater than -180",
 "OccurrenceStatus is Present",
 "Year is greater than or equal to 1950",
 "Year is less than or equal to 2014"
 ]
}

 The dataset includes 121 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006808-250227182400228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.28208789
title: <i>CYP2C19</i> and <i>CES1</i> gene variants affecting clopidogrel metabolism in a South Asian population from Sri Lanka

description: Clopidogrel exhibits substantial variability in therapeutic response, largely contributed by genetic factors. The pharmacogenomic variants data on clopidogrel metabolism in South Asians have been sparsely studied. This study explores the impact of <i>CYP2C19</i> and <i>CES1</i> gene variants on clopidogrel metabolism in Sri Lankans, revealing significant pharmacogenomic insights with broader implications for South Asians. Genotype data were filtered out from an anonymized database of 690 Sri Lankans, and minor allele frequencies (MAFs) were calculated. Five variants of <i>CYP2C19</i> and one variant of <i>CES1</i> gene were studied. Among the five <i>CYP2C19</i> variants studied, rs12769205 (A&gt;G) and rs4244285 (G&gt;A) had the highest MAF of 42.1% and 42.0%, respectively. The <i>CES1</i> variant rs71647871 (C&gt;T) showed a MAF of 0.2%. Sri Lankans exhibited significantly higher MAFs for key variants compared to populations such as Europeans, African Americans, and East Asians (<i>p</i> &lt; 0.05). Given that South Asians share genetic similarities, these findings suggest that a substantial proportion of the region’s population may also be poor responders to clopidogrel, increasing the risk of adverse outcomes. This highlights the importance of genotype-guided antiplatelet therapy, which could improve clinical outcomes across South Asia amidst rising cardiovascular disease rates.
DOI: 10.6084/m9.figshare.28208789.v1
title: <i>CYP2C19</i> and <i>CES1</i> gene variants affecting clopidogrel metabolism in a South Asian population from Sri Lanka

description: Clopidogrel exhibits substantial variability in therapeutic response, largely contributed by genetic factors. The pharmacogenomic variants data on clopidogrel metabolism in South Asians have been sparsely studied. This study explores the impact of <i>CYP2C19</i> and <i>CES1</i> gene variants on clopidogrel metabolism in Sri Lankans, revealing significant pharmacogenomic insights with broader implications for South Asians. Genotype data were filtered out from an anonymized database of 690 Sri Lankans, and minor allele frequencies (MAFs) were calculated. Five variants of <i>CYP2C19</i> and one variant of <i>CES1</i> gene were studied. Among the five <i>CYP2C19</i> variants studied, rs12769205 (A&gt;G) and rs4244285 (G&gt;A) had the highest MAF of 42.1% and 42.0%, respectively. The <i>CES1</i> variant rs71647871 (C&gt;T) showed a MAF of 0.2%. Sri Lankans exhibited significantly higher MAFs for key variants compared to populations such as Europeans, African Americans, and East Asians (<i>p</i> &lt; 0.05). Given that South Asians share genetic similarities, these findings suggest that a substantial proportion of the region’s population may also be poor responders to clopidogrel, increasing the risk of adverse outcomes. This highlights the importance of genotype-guided antiplatelet therapy, which could improve clinical outcomes across South Asia amidst rising cardiovascular disease rates.
DOI: 10.6084/m9.figshare.28233346.v1
title: Pharmacogenomic curriculum in Australian medical schools: a content analysis study

description: To ascertain and describe pharmacogenomic concepts included in the intended curriculum of accredited Australian medical schools. Content analysis of curriculum learning objectives of Australian medical schools was conducted, focusing on keywords and phrases pertaining to pharmacogenomic education. Learning objectives related to pharmacogenomics were categorized using (1) undergraduate medical genomic competencies per the Association of Professors in Human and Medical Genetics (2) Bloom’s Taxonomy for cognitive and knowledge dimensions and (3) knowledge translation (enabling science, translation science and clinical implementation). The curricula of 19 accredited medical schools in Australia were analyzed. Two-thirds (68%) contained genomic/pharmacogenomic education. Eight schools had content relating to undergraduate medical genomic competencies. Of those which had pharmacogenomic-related learning objectives, the majority (65%) were categorized in Bloom’s Taxonomy’s lower levels (Remember and Understand) and 15% were deemed to be at the level of ‘Clinical Implementation.’ The majority of Australian medical schools have incorporated pharmacogenomics in their current curriculum; however, learning objectives addressing application and clinical implementation are required. Doctors have a unique role to play in implementing pharmacogenomics into clinical practice. Comprehensiveness of course curricula across all learning domains would support uptake of pharmacogenomics into routine practice. <b>What is this article about?</b> Pharmacogenomics uses genetic information to individualize drug treatment and its use in medicine is rapidly expanding.  This article reviews pharmacogenomic education provided in Australian medical schools to understand how prepared medical graduates are to use pharmacogenomic concepts in daily practice. <b>What were the results?</b> The majority of Australian medical schools offer education regarding the science of pharmacogenomics; however, there is limited education on applying this information in the clinical setting to support patients and a multidisciplinary approach to care. <b>What do the results mean?</b> Australian medical schools should consider enhancing core pharmacogenomic clinical skills to utilize pharmacogenomics to its full potential.
DOI: 10.6084/m9.figshare.28367891
title: Biomarkers for the prediction and monitoring of the antipsychotic/antidepressant-induced hepatotoxicity: study protocol

description: This study is designed to address the connection between antidepressant and antipsychotic-induced hepatotoxicity with pharmacogenetic and epigenetic indicators, using a novel combined approach of CYP450 polymorphism determination and early liver injury detection via microRNA testing. The multi-centric retrospective case-control study in Slovakia involves 151 cases with signs of hepatotoxicity and 604 controls without. Participants will be tested for selected CYP450, UGT1A1 polymorphisms, and microRNAs. Anticipated findings will test if patients with specific CYP450 and UGT1A1 polymorphisms are at higher risk for drug-induced hepatotoxicity and if plasma microRNAs hsa-miR-122-5p and hsa-miR-192-5p, alone or combined, can differentiate patients with abnormal liver function. The findings could contribute to personalized treatment approach by combining genetic and epigenetic biomarkers. This study is about making treatment for mental health issues, like depression and anxiety, better and safer. Some patients respond differently to their medications, and some can have serious side effects, such as liver damage. To help with this, we are trying a new approach that uses two tests. The first test looks at certain genes to see how a person might react to medication. The second test checks for small molecules in the blood that can show if there are early signs of liver problems. We want to find out two things: Do people with certain genes have a higher risk of liver problems from their medications? Can these small molecules help us find liver issues better than regular blood tests? We will study about 755 patients from three mental health clinics in Slovakia, who have been taking their medications for at least four weeks. By identifying patients who might struggle with their medications due to their genes, we hope to catch liver problems early. This could lead to more personalized and effective treatments for everyone.
DOI: 10.6084/m9.figshare.28367891.v1
title: Biomarkers for the prediction and monitoring of the antipsychotic/antidepressant-induced hepatotoxicity: study protocol

description: This study is designed to address the connection between antidepressant and antipsychotic-induced hepatotoxicity with pharmacogenetic and epigenetic indicators, using a novel combined approach of CYP450 polymorphism determination and early liver injury detection via microRNA testing. The multi-centric retrospective case-control study in Slovakia involves 151 cases with signs of hepatotoxicity and 604 controls without. Participants will be tested for selected CYP450, UGT1A1 polymorphisms, and microRNAs. Anticipated findings will test if patients with specific CYP450 and UGT1A1 polymorphisms are at higher risk for drug-induced hepatotoxicity and if plasma microRNAs hsa-miR-122-5p and hsa-miR-192-5p, alone or combined, can differentiate patients with abnormal liver function. The findings could contribute to personalized treatment approach by combining genetic and epigenetic biomarkers. This study is about making treatment for mental health issues, like depression and anxiety, better and safer. Some patients respond differently to their medications, and some can have serious side effects, such as liver damage. To help with this, we are trying a new approach that uses two tests. The first test looks at certain genes to see how a person might react to medication. The second test checks for small molecules in the blood that can show if there are early signs of liver problems. We want to find out two things: Do people with certain genes have a higher risk of liver problems from their medications? Can these small molecules help us find liver issues better than regular blood tests? We will study about 755 patients from three mental health clinics in Slovakia, who have been taking their medications for at least four weeks. By identifying patients who might struggle with their medications due to their genes, we hope to catch liver problems early. This could lead to more personalized and effective treatments for everyone.
DOI: 10.6084/m9.figshare.28457380
title: Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic

description: Pharmacogenetic (PGx) screening is intended to optimize drug efficacy and reduce adverse drug reactions. Current screening options include genotyping assays for preselected PGx variants and broader next-generation sequencing panels (NGS). Few studies have directly compared preemptive PGx screening methods. The two PGx methods were compared in a cross-sectional study of adult Military Health System (MHS) clinic beneficiaries. Participants had initial targeted CYP2C19/CYP2D6 genotyping at a Military Health System Laboratory. Genotyping was followed by multi-gene NGS testing. Current prescriptions were recorded and potential drug–drug interactions screened to evaluate prescribing risk. All participants (100%) had at least one clinically actionable NGS panel result compared to 81% with targeted CYP2C19/CYP2D6 genotyping. Participants (<i>n</i> = 162) had an average of 6.6 (range 0–22) prescriptions and 2.7 (range 0–24) drug–drug interactions. Among those with at least one clinically actionable NGS result, 42% were currently taking medication with actionable CPIC guidelines (Level A/B), compared with 24% with CYP2C19/CYP2D6 genotyping. Sixteen participants (10%) had uncertain NGS panel results, with none for CYP2C19/CYP2D6 genotyping. Preemptive multi-gene NGS detected more clinically actionable PGx results than targeted <i>CYP2C19/CYP2D6</i> genotyping. Effective PGx screening in the MHS may decrease preventable adverse effects and improve military readiness.
DOI: 10.6084/m9.figshare.28457380.v1
title: Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic

description: Pharmacogenetic (PGx) screening is intended to optimize drug efficacy and reduce adverse drug reactions. Current screening options include genotyping assays for preselected PGx variants and broader next-generation sequencing panels (NGS). Few studies have directly compared preemptive PGx screening methods. The two PGx methods were compared in a cross-sectional study of adult Military Health System (MHS) clinic beneficiaries. Participants had initial targeted CYP2C19/CYP2D6 genotyping at a Military Health System Laboratory. Genotyping was followed by multi-gene NGS testing. Current prescriptions were recorded and potential drug–drug interactions screened to evaluate prescribing risk. All participants (100%) had at least one clinically actionable NGS panel result compared to 81% with targeted CYP2C19/CYP2D6 genotyping. Participants (<i>n</i> = 162) had an average of 6.6 (range 0–22) prescriptions and 2.7 (range 0–24) drug–drug interactions. Among those with at least one clinically actionable NGS result, 42% were currently taking medication with actionable CPIC guidelines (Level A/B), compared with 24% with CYP2C19/CYP2D6 genotyping. Sixteen participants (10%) had uncertain NGS panel results, with none for CYP2C19/CYP2D6 genotyping. Preemptive multi-gene NGS detected more clinically actionable PGx results than targeted <i>CYP2C19/CYP2D6</i> genotyping. Effective PGx screening in the MHS may decrease preventable adverse effects and improve military readiness.
DOI: 10.6084/m9.figshare.28233346
title: Pharmacogenomic curriculum in Australian medical schools: a content analysis study

description: To ascertain and describe pharmacogenomic concepts included in the intended curriculum of accredited Australian medical schools. Content analysis of curriculum learning objectives of Australian medical schools was conducted, focusing on keywords and phrases pertaining to pharmacogenomic education. Learning objectives related to pharmacogenomics were categorized using (1) undergraduate medical genomic competencies per the Association of Professors in Human and Medical Genetics (2) Bloom’s Taxonomy for cognitive and knowledge dimensions and (3) knowledge translation (enabling science, translation science and clinical implementation). The curricula of 19 accredited medical schools in Australia were analyzed. Two-thirds (68%) contained genomic/pharmacogenomic education. Eight schools had content relating to undergraduate medical genomic competencies. Of those which had pharmacogenomic-related learning objectives, the majority (65%) were categorized in Bloom’s Taxonomy’s lower levels (Remember and Understand) and 15% were deemed to be at the level of ‘Clinical Implementation.’ The majority of Australian medical schools have incorporated pharmacogenomics in their current curriculum; however, learning objectives addressing application and clinical implementation are required. Doctors have a unique role to play in implementing pharmacogenomics into clinical practice. Comprehensiveness of course curricula across all learning domains would support uptake of pharmacogenomics into routine practice. <b>What is this article about?</b> Pharmacogenomics uses genetic information to individualize drug treatment and its use in medicine is rapidly expanding.  This article reviews pharmacogenomic education provided in Australian medical schools to understand how prepared medical graduates are to use pharmacogenomic concepts in daily practice. <b>What were the results?</b> The majority of Australian medical schools offer education regarding the science of pharmacogenomics; however, there is limited education on applying this information in the clinical setting to support patients and a multidisciplinary approach to care. <b>What do the results mean?</b> Australian medical schools should consider enhancing core pharmacogenomic clinical skills to utilize pharmacogenomics to its full potential.
DOI: 10.15468/dl.h8ehj9
title: Occurrence Download

description: A dataset containing 1086 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Ireland",
 "TaxonKey is Myodes glareolus (Schreber, 1780)"
 ]
}

 The dataset includes 1086 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006807-250227182400228/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7pmagc
title: Occurrence Download

description: A dataset containing 11 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Pastinaca sativa L.",
 "Geometry POLYGON((-4.57907617500001 39.884719509, -4.57907617500001 41.165844755, -3.05298331400002 41.165844755, -3.05298331400002 39.884719509, -4.57907617500001 39.884719509))"
 ]
}

 The dataset includes 11 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006826-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wze3n5
title: Occurrence Download

description: A dataset containing 52465 species occurrences available in GBIF matching the query:
{
 "and" : [
 {
 "or" : [
 "Geometry POLYGON((12.49858 -13.65524,17.99754 -13.7675,18.02681 -11.24187,12.62671 -11.24187,12.49858 -13.65524))",
 "Geometry POLYGON((18.0023 -13.18233,22.72837 -13.10343,22.72837 -10.28872,18.04173 -10.28872,18.0023 -13.18233))"
 ]
 },
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 52465 records from 288 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006798-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.a8m8sj
title: Occurrence Download

description: A dataset containing 55 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Asia",
 "Country is China",
 "TaxonKey is Ageratina adenophora (Spreng.) R.M.King & H.Rob."
 ]
}

 The dataset includes 55 records from 9 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006827-250227182430271/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.